Accession Number:

AD1166789

Title:

Do Black Men with Metastatic Castration-Resistant Prostate Cancer Have Worse Outcomes Than White Patients? A Nationwide VA Study

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

CEDARS-SINAI MEDICAL CENTER LOS ANGELES CA

Personal Author(s):

Report Date:

2021-10-01

Pagination or Media Count:

14

Abstract:

Black men have a higher prostate cancer PC risk and mortality than white men. Whether these differences are due to lack of access to care or more aggressive biology is debated. However, a few small studies suggested black men may actually have better outcomes than white men when treated with metastatic castration-resistant PC mCRPC drugs. We hypothesize that black men with mCRPC will have similar responses to modern mCRPC therapies but worse compliance after accounting for poorer compliance, black men will actually have better responses to these therapies than white men. Our objective is, to create a true nation-wide cohort from the Veterans Affairs VA Health System. Our preliminary analyses identified 46,535 men treated with one of 6 drugs for mCRPC Cabazitaxel, Docetaxel, Abiraterone, Enzalutamide, Radium-223, and Sipuleucel-T. We will 1. Determine drug efficacy among black and white men with mCRPC 2. Determine drug compliance among black and white men with mCRPC and 3. Determine drug efficacy among black and white men with mCRPC after accounting for compliance.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]